Comparing the Effect of Sevelamer Hydrochloride and Calcium Carbonate on Serum Level of Inflammatory Markers in Hemodialysis Patients

Comparing the Effect of Sevelamer Hydrochloride and Calcium Carbonate on Serum Level of hs-CRP, Soluable CD-14 and Endotoxin in Hemodialysis Patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200724048193N1

Enrollment

Registered

2020-11-15

Start date

2020-10-22

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease. Hypertensive heart and chronic kidney disease without heart failure, with stage 5 chronic kidney disease, or end stage renal disease

Interventions

Intervention 1: Intervention group: Receiving 800 mg Sevelamer Hydrochloride tablets product by Faran Shimi pharmaceutical 3 times a day with meal for 2 months. Intervention 2: Intervention group: Rec

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with ESRD Indication of treatment with phosphate binders Hemodialysis preformation for more than three months

Exclusion criteria

Exclusion criteria: Impossibility of alternative treatment with Sevelamer Hydrochloride or Calcium Carbonate Cigarette, alcohol and drug abuse History of immunological diseases Any type of cancer Recent active infection Previous kidney transplant history History of receiving immunosuppressive treatment

Design outcomes

Primary

Measure	Time frame
Endotoxin. Timepoint: At the beginning of the study and two months after starting treatment. Method of measurement: Serum level measurement.;High-sensitivity C-reactive protein. Timepoint: At the beginning of the study and two months after starting treatment. Method of measurement: Serum level measurement.;Soluable CD-14. Timepoint: At the beginning of the study and two months after starting treatment. Method of measurement: Serum level measurement.	—

Measure

Time frame

Endotoxin. Timepoint: At the beginning of the study and two months after starting treatment. Method of measurement: Serum level measurement.;High-sensitivity C-reactive protein. Timepoint: At the beginning of the study and two months after starting treatment. Method of measurement: Serum level measurement.;Soluable CD-14. Timepoint: At the beginning of the study and two months after starting treatment. Method of measurement: Serum level measurement.

—

Secondary

Measure	Time frame
Possible side effects. Timepoint: Two months after starting treatment. Method of measurement: Assessment and questioning of the patient.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShabnam Salehi

Tabriz University of Medical Sciences

salehish@tbzmed.ac.ir+98 41 3337 3966

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026